Form 4: Corcept Therapeutics CEO Joseph Belanoff Sells Shares Under 10b5-1 Trading Plan

Corcept Therapeutics CEO Joseph K. Belanoff executed sales of common stock on May 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 2, 2025, Joseph K. Belanoff, CEO of Corcept Therapeutics, sold shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• A total of 18,480 shares were sold at a weighted average price of $72.5187, with prices ranging from $72.13 to $72.99 per share.
• An additional 21,520 shares were sold at a weighted average price of $73.2238, with prices ranging from $73.00 to $73.65 per share.
• Following these transactions, Belanoff directly owns 2,963,505 shares and indirectly owns 2,941,985 shares through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating stock sales by an insider. It's neutral in tone and doesn't inherently suggest positive or negative sentiment about the company's prospects.

Industry Context

Sales by corporate insiders are a common occurrence and are often pre-planned under Rule 10b5-1 to avoid accusations of trading on material non-public information. The market typically analyzes the size and frequency of such sales to gauge insider sentiment.

Stakeholder Impact

• Shareholders may interpret the stock sales as a sign of the CEO's sentiment, although the Rule 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Corcept Therapeutics, CORT, Joseph K. Belanoff, Stock Sale, Form 4, Rule 10b5-1, Insider Trading